A portable BRCA1-HAC (human artificial chromosome) module for analysis of BRCA1 tumor suppressor function by Kononenko, Artem V. et al.
Published online 26 September 2014 Nucleic Acids Research, 2014, Vol. 42, No. 21 e164
doi: 10.1093/nar/gku870
A portable BRCA1-HAC (human artificial
chromosome) module for analysis of BRCA1 tumor
suppressor function
Artem V. Kononenko1, Ruchi Bansal2, Nicholas C.O. Lee1, Brenda R. Grimes2,
Hiroshi Masumoto3, William C. Earnshaw4, Vladimir Larionov1 and Natalay Kouprina1,*
1Developmental Therapeutics Branch, National Cancer Institute, Bethesda, MD 20892, USA, 2Department of Medical
and Molecular Genetics, Indiana University School of Medicine, Indiana University Melvin and Bren Simon Cancer
Center, Indianapolis, IN 46202, USA, 3Laboratory of Cell Engineering, Department of Frontier Research, Kazusa
DNA, Research Institute, 2-6-7 Kazusa-Kamatari, Kisarazu, Chiba 292-0818, Japan and 4Wellcome Trust Centre for
Cell Biology, University of Edinburgh, Edinburgh EH9 3JR, Scotland
Received August 04, 2014; Revised September 03, 2014; Accepted September 10, 2014
ABSTRACT
BRCA1 is involved in many disparate cellular func-
tions, including DNA damage repair, cell-cycle check-
point activation, gene transcriptional regulation,
DNA replication, centrosome function and others.
The majority of evidence strongly favors the mainte-
nance of genomic integrity as a principal tumor sup-
pressor activity of BRCA1. At the same time some
functional aspects of BRCA1 are not fully under-
stood. Here, a HAC (human artificial chromosome)
module with a regulated centromere was constructed
for delivery and expression of the 90 kb genomic
copy of the BRCA1 gene into BRCA1-deficient hu-
man cells. A battery of functional tests was carried
out to demonstrate functionality of the exogenous
BRCA1. In separate experiments, we investigated the
role of BRCA1 in maintenance of heterochromatin
integrity within a human functional kinetochore. We
demonstrated that BRCA1 deficiency results in a spe-
cific activation of transcription of higher-order alpha-
satellite repeats (HORs) assembled into heterochro-
matin domains flanking the kinetochore. At the same
time no detectable elevation of transcription was ob-
served within HORs assembled into centrochromatin
domains. Thus, we demonstrated a link between
BRCA1 deficiency and kinetochore dysfunction and
extended previous observations that BRCA1 is re-
quired to silence transcription in heterochromatin in
specific genomic loci. This supports the hypothesis
that epigenetic alterations of the kinetochore initi-
ated in the absence of BRCA1 may contribute to cel-
lular transformation.
INTRODUCTION
BRCA1 is a well-known tumor suppressor gene, germ line
mutations inwhich predisposewomen to breast and ovarian
cancers. Since the identification of the BRCA1 gene, there
have been numerous studies aimed at characterizing the di-
verse repertoire of its biological functions. BRCA1 is in-
volved in multiple cellular pathways, including DNA dam-
age repair, chromatin remodeling, X-chromosome inactiva-
tion, centrosome duplication and cell-cycle regulation (1–
7). A recent study has suggested a role in the epigenetic reg-
ulation of an oncogenic microRNA (8).
BRCA1 associates with constitutive pericentromeric het-
erochromatin in nuclei (1). Further insight into the role of
BRCA1 in pericentromeric heterochromatin and a signifi-
cant link to maintaining global heterochromatin integrity
has been recently gained by Zhu et al. (9). They showed
that loss of BRCA1 results in transcriptional de-repression
of tandemly repeated satellite DNA in mice and human
BRCA1-deficient cells. This impairment of constitutive het-
erochromatin may lead to de-repression of the normally si-
lenced genes that are located at the tandemly repeatedDNA
regions, probably through the loss of ubiquitylation of his-
toneH2A. These effects on heterochromatin silencing could
potentially account for some aspects of BRCA1 tumor sup-
pression function.
In their experiments, the authors employed a lentivirus
vector expressing aBRCA1 cDNA to complement BRCA1-
deficiency. Such an approach may not completely recapitu-
late the physiological expression of theBRCA1 gene for sev-
eral reasons. These include the lack of a strong copy number
control of the transgene, the lack of alternative splice-forms
when rescuing function with a cDNA and the absence of
the intronic regions of the gene, which may include regu-
latory elements, and which, when spliced, will increase the
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efficiency of translation of the resulting mRNA (10–14).We
therefore hypothesized that delivery of an entire, single copy
of the BRCA1 genomic locus may provide additional infor-
mation on BRCA1 function.
The use of an alternative HAC-based (human artificial
chromosome) vector for gene delivery and expression may
potentially overcome some of the limitations associated
with the viral-based delivery of the BRCA1 cDNA outlined
above. HACs are de novo chromosomes that contain func-
tional centromeres permitting their long-term stable main-
tenance as single copy mini-chromosomes without integra-
tion into the host chromosomes. This minimizes such com-
plications as disruption of endogenous genes (15–18 and
references therein). Moreover, HAC vectors have unlimited
cloning capacity allowing them to carry entire genomic loci
or potentially groups of loci with all regulatory elements
that should faithfully mimic the normal pattern of gene ex-
pression. At present the carrying capacity is limited to sev-
eral megabases (Mb) only by technical cloning limitations.
A structurally characterizedHAC, alphoidtetO-HAC (19–
21) with a single gene loading site, has ideal features re-
quired for gene function studies. A unique advantage of this
HAC is its regulated kinetochore, which provides a unique
possibility to compare the phenotypes of the human cell
with and without a functional copy of a gene (19). This pro-
vides a pure control for phenotypic changes attributed to ex-
pression of a HAC-encoded gene by returning the mutant
cell line to its original state following loss of the HAC (22).
Inactivation of theHAC centromere is accomplished by tar-
geting tet-repressor (tetR) fusion proteins to the alphoid
DNA array of the HAC, which contains ∼3000 tetracy-
cline operator (tetO) sequences embedded into each alphoid
DNA unit. Certain chromatin-modifying fusion proteins,
such as the tTS, inactivate the HAC centromere so that its
segregation becomes random and it is gradually lost from
growing populations of cells.
In the present study, a 90 kb genomic region spanning the
BRCA1 gene, which includes potential regulatory elements
in intron regions (23) was inserted into the alphoidtetO-
HAC and subsequently used to complement a BRCA1 gene
deficiency in human ovarian cancer cell line UWB1.289.
The full-length BRCA1 genomic locus was selectively iso-
lated from total genomic DNA by the TAR cloning tech-
nique (24,25). Functional expression of BRCA1 in BRCA1-
deficient recipient cells was confirmed by a set of specific
tests based on the known functions of the BRCA1 protein.
In addition, we extended a previous observations of Zhu
et al. (9) that BRCA1 is required to silence transcription
in heterochromatin in a genomic locus-specific manner. In
the separate experiments, using recently released sequence
information on higher-order alpha-satellite centromeric re-
peats (HORs) (26), we used the BRCA1-HAC module to
demonstrate a direct link between BRCA1 deficiency and
kinetochore dysfunction.
MATERIALS AND METHODS
Cell lines
Hypoxanthine phosphoribosyltransferase (HPRT)-
deficient Chinese hamster ovary (CHO) cells (JCRB0218)
carrying the alphoidtetO-HAC were maintained in Ham’s
F-12 nutrient mixture (Invitrogen, USA) plus 10% fe-
tal bovine serum (FBS) with 8 g/ml Blasticidin S
Hydrochloride (Funakoshi, Japan). After insertion of
a TAR/BAC/BRCA1 construct and the eGFP gene
into alphoidtetO-HAC, CHO cells retaining the tetO-
eGFP-BRCA1-HAC were maintained in HAT-containing
medium. The BRCA1-deficient human ovarian cancer
cell line UWB1.289 carrying a germline BRCA1 mutation
within exon 11 and having a deletion of the wild-type
allele (27) was obtained from the American Type Culture
Collection (ATCC; Manassas, USA). These cells were
maintained in 50% RPMI1640 medium containing 50%
MEGM (Mammary Epithelial Growth Medium from
Clonetics/Lonza) (MEGM Bullet Kit; CC3150) made
of Mammary Epithelial Basal Medium (MEBM) basal
medium and SingleQuot plus 3% FBS. Swine testis (ST)
cells (ATCCRCRL-1746) were obtained from the ATCC.
The base medium for ATCCRCRL-1746 cells is ATCC-
formulated Eagle’s Minimum Essential Medium (Catalog
No. 30–2003) plus 10% of FBS.
Retrofitting of YAC/BRCA1 into a BAC
A diagram of the retrofitting of a circular YAC/BRCA1
molecule into a BAC form is shown in Supplementary Fig-
ure S2. Retrofitting vector pJBRV1 (22) contains theURA3
yeast selectable marker, F’ factor origin replication, the
chloramphenicol acetyltransferase (CmR) gene and a cas-
sette including a 3′ end of the HPRT gene, the eGFP gene,
a loxP sequence and two short targeting hooks (∼300 bp
each) separated by the unique BamHI site. These targeting
hooks flank the ColE1 origin of replication in the pVC604-
based TAR cloning vector that was previously used to clone
a 90 kb genomic copy of the BRCA1 gene (23). Recom-
bination of the BamHI-linearized pJBRV1 vector with the
pVC604 vector carrying the BRCA1 gene in yeast leads to
replacement of the ColE1 origin of replication by a cassette
containing the F’ factor, the CmR gene, theURA3 gene and
3′-HPRT-loxP-eGFP sequences. For retrofitting, a standard
lithium acetate transformation procedure in yeast Saccha-
romyces cerevisiae strain VL6–48 (MATa, his3-Δ200, trp1-
Δ1, ura3–52, lys2, ade2–101, met14) was used. This strain
is available under request from the Development Therapy
Branch, National Cancer Institute (NCI, NIH) or alterna-
tively from the ATCC (ATCC Number MYA-3666). The
YAC/BACs were transferred into Escherichia coli by elec-
troporation. In brief, yeast chromosome-size DNAwas pre-
pared in agarose plugs and, after melting and agarase treat-
ment, the DNAs were electroporated into DH10B compe-
tent cells (GIBCO/BRL) by using a Bio-Rad Gene Pulser
as previously described (22).
Loading of BAC/BRCA1 into the loxP site of the alphoidtetO-
HAC in CHO cells
Loading of the BRCA1 gene into HAC was performed us-
ing Cre-recombinase as previously described (20). Twenty
micrograms of the BAC vector containing the BRCA1 gene
and 1 microgram of the Cre expression pCpG-iCre vector
were co-transformed into HPRT-deficient CHO cells (105)
containing the alphoidtetO-HAC vector by lipofection using
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either FuGENERHD transfection reagent (Roche) or Lipo-
fectamine 2000 (Invitrogen). HPRT-positive colonies were
selected after 3 weeks growth in HAT medium. Insertion
of BRCA1 into the alphoidtetO-HAC was confirmed by ge-
nomic polymerase chain reaction (PCR) with a specific pair
of primers that diagnose reconstitution of the HPRT gene
(Supplementary Table S1). Four colonies were confirmed to
contain all exons of BRCA1. One clone was chosen for fur-
ther analysis.
Microcell-mediated chromosome transfer (MMCT)
alphoidtetO-HAC/BRCA1 was transferred from hamster
CHO cells to the human UWB1.289 cell line deficient
for the BRCA1 gene and ST cells using MMCT proto-
col described previously (28,29) with minor modifications.
First, six Nunc T24 flat flasks of CHO cells containing
alphoidtetO-HAC/BRCA1 were grown to 70–80% conflu-
ence in 4 ml per flask of F12 media supplemented with
10% FBS. Then the media was changed to fresh media con-
taining 0.1 g/ml colcemid. The cells were grown with col-
cemid for ∼72 h. The media was then aspirated and each
flask filled up to neck with a solution of 10 g/ml Cytocha-
lacin B in serum-free Dulbecco’s modified Eagle’s medium
(DMEM) (Cyto-Bmedium), pre-heated to 37◦C, then incu-
bated 30 min at 37◦C. Parafilm was used to seal T24 flask.
T24 culture flask was stuck to a large centrifuge bottle us-
ing laboratory labeling tape with the flat side toward the ro-
tor. The bottles were filled to about 1/3 with pre-warmed
37◦Cwater. Then these six bottles containing the T24 flasks
were spun at 7000–7500 revolutions per minute (rpm), 37◦C
for 60 min in a Sorvall RC 5B. The Cyto-B medium was
removed after centrifugation. The Cyto-B medium can be
re-used several times after filtration via 0.22 m filter. Two
milliliters of DMEM serum-free mediumwas added to each
flask. Microcells were washed with 5 ml pipette and the sus-
pension of microcells was transferred into 15 ml tube. Then
an additional 2 ml was used to wash all tubes to get as
much microcells as possible. Microcell suspension was in-
cubated at 4◦C for 20 min. The microcell suspension was
filtered sequentially through the sterile 8, 5 and 3 m Iso-
pore Membranes (Millipore, # TETP02500, #TMTP02500
and # TSTP02500) using 6–7 ml suspension for 1 filter set.
After filtration, the 15 ml tube containing filtered micro-
cells was centrifuged at 2200 rpm for 10 min. The super-
natant was aspirated and the microcells were washed by
1 ml of ice cold Hemagglutinating Virus of Japan (HVJ)
buffer [GenomONE-CFEXSeV-E(HVJ-E) 1Vials Cell Fu-
sion Reagents, Cosmo Bio Co., LTD, # ISK-CF-001-EX],
and centrifugated for 5 min at 3000 rpm. The supernatant
was removed and the microcells were suspended in 50 l ice
cold HVJ suspension buffer and then kept on ice. During
microcell centrifugation step, the recipient cells UWB1.289
cells were split 2 days before MMCT experiment to reach
∼80–90% of confluence by the MMCT day. The cells were
trypsinized, washed by complete growthmedia to inactivate
trypsin and resuspended in 1 ml of ice cold HVJ buffer, cen-
trifuged for 1 min at 2000 rpm. The supernatant was aspi-
rated and the cells were resuspended in 50 l of ice cold
HVJ buffer and kept on ice. Suspensions of cells and mi-
crocells were mixed together and ice-cooled 10 l of HVJ
viral envelop protein (GenomONE-CF EX SeV-E(HVJ-E)
1 Vials Cell fusion Reagents) was added and mixed by tap-
ping. The mixture was left on ice for 5 min to allow HVJ-
E to be adsorbed on the cell/microcell surface, then in-
cubated at 37◦C for 15 min when mixing by tapping ev-
ery 5 min to induce cell/microcell fusion. The complete
growth medium was added to the tube containing mixture
cells/microcells and transferred to a 10-cmplate for cell pro-
liferation and growth. The alphoidtetO-HAC/BRCA1 car-
ries Bsr genes, thus Blasticidin (BS) was used to select for
cells that have taken up the HAC. Blasticidin (2–4 g/ml)
was added in 2 days after MMCT. The blasticidin resistant
colonies were isolated in 4–6 weeks after selection. Typically
1–3 BSR colonies were obtained in one MMCT experiment
involving HAC transfer into the gene-deficient cells. BSR
clones were analyzed by fluorescence in situ hybridization
(FISH). Based on FISH analysis, more than 95% of cells
in the colony contained a HAC. No co-transfer of CHO
chromosomes was detected in our experiments using a sen-
sitive PCR test for rodent SINE elements-hamster B2 re-
peats (Supplementary Table S1).
FISH analysis
FISH and immuno-FISH analyses were performed as pre-
viously described (19,20) with minor modifications. HAC-
containing cells were cultured in medium with 0.1 mg/ml
of colcemid (Invitrogen, #15212-012) for 3 h at 37◦C.
Metaphase cells were trypsinized and collected by centrifu-
gation for 2 min at 1000 rpm, treated in hypotonic solu-
tion (50 mM KCl) for 20 min at 37◦C and washed three
times in methanol:acetic acid (3:1) fixative solution. Cells
were diluted to the appropriate density with fixative solu-
tion, spread onto pre-cleaned slides (Fisher Scientific, # 12-
544-7) above of steam (boiling water), check on microscope
and when slide is fine allowed to age 2 days at room temper-
ature.Metaphase chromosomes on the slide were denatured
by denaturation buffer 70% formamide/2xSSC for 2 min at
72◦C. Samples were dehydrated through a 70%, 90% and
100% ethanol series for 4 min each and left to air-dry. Or-
ange 552 dUTP (5-TAMRA-dUTP) (AbbottMolecular) or
Green 496 [5-Fluorescein] dUTP (Abbott Molecular) and
Red 650 [Cyanine-5E] dUTP (Enzo) labeled probes were de-
natured in hybridization solution at 78◦C for 10min and left
at 37◦C for 30min. The hybridizationmix probe (or probes)
was applied to the sample and incubated at 37◦C overnight.
Slides were washed with 0.4× SSC, 0.3%Tween 20 for 2min
at 72◦C, briefly rinsed with 2× SSC, 0.1% Tween 20 (5 s–
1 min) and air-dried in darkness for 30 min. The samples
were counterstained with Vectashield mounting medium
with 4′,6-diamidino-2-phenylindole (DAPI) (Vector Labs).
Slides were analyzed by fluorescence microscopy. Images
were captured using a DeltaVision microscopy imaging sys-
tem in the CRC, LRBGE Fluorescence Imaging Facility
(NIH) and analyzed using image J software (NIH).
The probes used for FISH analysis
The probes used for FISH were BAC32-2-mer (tetO) DNA
containing a 40 kb of alphoid-tetO array cloned into a BAC
vector as described previously (19) and cDNA of BRCA1.
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BAC DNA was labeled using a nick-translation kit with
Orange 552 dUTP (5-TAMRA-dUTP) (Abbott Molecu-
lar) or Red 650 [Cyanine-5E] dUTP (Enzo) for two col-
ors FISH with cDNA. cDNA was labeled by Green 496 [5-
Fluorescein] dUTP (Abbott Molecular).
Genomic DNA preparation
For PCR analysis, genomic DNA from hamster CHO
and human UWB1.289 cells containing the alphoidtetO-
HAC/BRCA1 was prepared using a DNeasy Blood & Tis-
sue Kit (Qiagen, #69506). Integrity of the BRCA1 gene was
confirmed by a set of primers for exonic regions of the gene.
These primers are listed in Supplementary Table S1. PCR
products were separated by agarose gel electrophoresis, gel
extracted and used for sequencing.
Antibodies
The following antibodies were used for immunoblot-
ting, co-immunoprecipitation and immunostaining: anti-
BRCA1 (Ab-1) (Catalog#OP92) mouse mAb (MS110)
(Calbiochem, EMD Millipore), anti-pol , anti-phospho-
histone H2A.X (Ser139) clone JBW301 (Millipore, # 05–
63), Alexa Fluor 555 Goat anti-mouse antibody (Red)
(H+L) (Life Technology, #A-21422), anti-Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) antibody (14C10)
rabbit mAb (Cell Signaling Technology, # 2118). For chro-
matin immunoprecipitation (ChIP) assay: H3K9me3 (Mil-
lipore, #07–523), H3K4me3 (Millipore, # 07–473) and
anti-CENP-A. Pol  antibodies were kindly provided by
Dr. Samuel H. Wilson (Laboratory of Structural Biol-
ogy, NIEHS). CENP-A antibodies were previously de-
scribed (30).
Western analysis
BRCA1 detection using western blotting was performed as
following. Briefly, the primary antibodies against BRCA1
(1:50 dilution) and against GAPDH (1:20 000 dilution)
were used. GAPDH was used as a loading control. Washes
were carried out with Tris-buffered Saline Tween 20 (TBST)
buffer (10mMTris-HCl pH8.0, 150mMNaCl, 0.5%Tween
20) for 30 min with 5 buffer changes. Secondary antibodies
used were: Amersham ECL, HRP-linked anti-mouse (1:10
000 dilution) (GE Healthcare, #NA931-1ML) for BRCA1
and Amersham ECL, HRP-linked anti-rabbit (GE Health-
care, #NA934-1ML) (1:10 000 dilution) for GAPDH.
Reverse-transcriptase PCR (RT-PCR)
Transcription of the BRCA1 gene from alphoidtetO-
HAC/BRCA1 in CHO, UWB1.289 and ST cell lines was
detected by RT-PCR using specific primers listed in Supple-
mentary Table S1. The PCR products were sequenced using
a PE-Applied Biosystem 3100 Automated Capillary DNA
Sequencer.
alphoidtetO-HAC/BRCA1 elimination by its targeting with
chromatin modifiers
Transient expression of the tTS-tet-repressor fusion pro-
tein to induce the HAC loss was performed as previously
described (20,22). After transfection with the tTS fusion
construct or empty vector as control, neomycin-resistant
clones were selected in the presence of doxycycline, condi-
tions that support proper HAC segregation and HAC sta-
bility (the tTS cannot bind to tetO sites). The HAC elim-
ination assay was then performed by transfer of the sta-
ble transfectants to media lacking doxycycline. After 48 h
of culturing in the presence of neomycin (800 g/ml), a
fraction of the HAC-less cells was detected by loss of the
eGFP signal. The cells that have lost the HACwere selected
for the further analysis. Selection of the HAC-less clones
takes ∼3 weeks. The absence of the HAC was confirmed by
FISH and western blot analyses. HAC-less cells were used
as controls for the restoration of the original mutant phe-
notypes. In separate experiments the cells were sorted us-
ing a fluorescence-activated cell sorting (FACS) AriaII cy-
tometer. After cell sorting, two populations of cells, green-
containing alphoidtetO-HAC/BRCA1 and non-green (after
HAC loss), were cultured independently and used for func-
tional studies.
ChIP analysis
ChIP was carried out according to a previously de-
scribed method (31). Cultured cells were cross-linked in 1%
formaldehyde for 10 min at 37◦C. After addition of 1/10
volume of 1.25 M glycine and incubation for 5 min, fixed
cells were washed twice with cold phosphate buffered saline
(PBS) buffer. Soluble chromatin was prepared by sonica-
tion in water bath-based sonicator (Bioruptor sonicator;
CosmoBio) to an averageDNA size of 500 bp and immnno-
precipitated in IP buffer (0.01% sodium dodecyl sulphate
(SDS), 1.1% Triton X- 100, 1.2 mM ethylenediaminete-
traacetic acid, 16.7 mM Tris-HCl, pH 8.1, 167 mM NaCl).
Protein A agarose/salmon Sperm DNA (Millipore, #16–
157) was added, and the antibody-chromatin complex was
recovered by centrifugation. The recovery ratio of the im-
munoprecipitated DNA relative to input DNA was mea-
sured by real-time PCRusing a 7900HTFast real-time PCR
detection system (Applied Biosystems) and SYBR Green
PCRMasterMix (Applied Biosystems, #4309155). Primers
for HORs regions of chromosome 21 and chromosome X,
tetO-2 mer of the alphoidtetO DNA array, HORs D5Z1 and
D5Z2 regions of chromosome 5 were described previously
(30,32) (see also Supplementary Table S1).
Co-immunoprecipitation of BRCA1 and DNA polymerase
pol 
The method was described previously (33) and was applied
with minor modifications. Two cell lines were grown to con-
fluence, the UWB1.289 cell line carrying alphoidtetO-HAC
/BRCA1 and the isogenic strain that have been induced
to lose the HAC. Approximately 15 million cells were har-
vested from each cell line and individually re-suspended
in 1.8 ml of lysis buffer (50 mM Tris-HCl, pH 7.5, 150
mM NaCl, 25 mM NaF, 0.1 mM sodium orthovanadate,
0.2% Triton X-100, 0.3%Nonidet P-40 with 1× protease in-
hibitor cocktail) and incubated on ice for 30 min. For each
sample, the lysate was centrifuged at 14 000 rpm for 30 min
at 4◦Cand the supernatant fractionwas transferred to a new
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tube. The protein concentration in the extract was deter-
mined using the Bio-Rad protein assay with bovine serum
albumin (BSA) as standard. For co-immunoprecipitation,
40 l of affinity purified anti-pol  polyclonal antibody or
10 l of rabbit non-immune immunoglobulin G (IgG; Up-
state, Millipore, #12–370) was added to equal amounts of
cell lysate (6mg of total proteins), and themixture was incu-
bated with rotation overnight at 4◦C. The immunocomplex
was adsorbed onto 30l suspension of protein A-sepharose
(Millipore) beads (pre-washed three times with lysis buffer)
by incubating the mixture for 6 h at 4◦C. The beads were
then washed three times with 600 l of lysis buffer contain-
ing protease inhibitors, with a 2 min, 2000 rpm centrifuge
spin between washes. Finally, the beads were re-suspended
in 30 l of SDS sample buffer, heated for 5 min and the
soluble proteins were separated by NuPAGE Novex 3–8%
Tris-Acetate Protein gel (Life Technology, EA0378BOX).
Proteins were transferred onto a nitrocellulose membrane
in BioRad transblot apparatus overnight at 5 V and were
analyzed by western blot with anti-BRCA1 (Ab-1) (Cata-
log#OP92), mouse mAb (MS110) antibody or anti-pol 
polyclonal antibody.
Micronucleus formation assay (MNi)
UWB1.289 cells were grown to 70–80% confluency, har-
vested and seeded at 20 000 cells/ml onto chamber slides.
After 24 h, cells were washed with 1× PBS, incubated
with 0.075 M KCl for 10 min, fixed in ice cold 3:1 v/v
methanol:acetic acid and dried overnight under vacuum.
The frequency of micronucleated cells was assessed using
fluorescence microscopy following DAPI staining.
Quantification of transcripts
Real-time RT-PCR with RNA purified from UWB1.289
cells carrying alphoidtetO-HAC/BRCA1 and from
UWB1.289 cells that have lost the HAC was carried
out using SYBR Green PCRMaster Mix (Applied Biosys-
tems, #4309155) and TaqMan Gene Expression Master
Mix (Applied Biosystems, #4369016) according to the
manufacturer’s protocol. Total RNA was prepared with
the RNeasy Mini Kit (Qiagen, #74104) with on column
DNase treatment using RNase-Free DNase Set (Qiagen,
#79254). First-strand cDNA synthesis was performed
using Moloney Murine Leukemia Virus Reverse Transcrip-
tase (M-MLV RT) (Invitrogen, #28025-013) according
to the manufacturer’s protocol. Reverse transcription
and PCR were carried out with the primers listed in
Supplementary Table S1.
Gamma irradiation
Radiation sensitivity of UWB1.289 cells carrying
alphoidtetO-HAC/BRCA1 and the same cells that have lost
the HAC was evaluated using the method described previ-
ously (34). Exponentially growing cells were suspended to
600–700 cells per 10 ml in sterile 50 ml tube with complete
medium in total volume 50 ml and plated in 5–10 cm plates
(Nunc) by 10 ml of cell suspension in each plate (600–700
cells per plate). After cells attachment in 12 h, the cells were
irradiated at room temperature using a 60Co  -ray source at
a dose rate of 2, 4, 6 and 8 Gy. After irradiation, plates were
placed in 10% CO2 incubator at 37◦C and removed after
2 weeks for analysis when the colonies were formed. The
percentage of survived cells were counted and normalized
to the number of colonies counted in unirradiated control
cells.
Immunofluorescence
Gamma-H2AX foci accumulation in UWB1.289 cells car-
rying alphoidtetO-HAC/BRCA1 and in the same cells that
have lost the HAC before and after exposure to 2 Gy
of gamma-radiation was measured as previously described
with minor changes (35). Note that 5× 104 cells were plated
onto sterile glass coverslips (Fisher finest Superslip, round,
thickness 1), placed into 12-well plates and grown to ∼80%
confluence. The plates were then irradiated using 2 Gy. Fol-
lowing irradiation, cells were placed in the incubator and
processed at stated repair times (15 h post-radiation). Cells
attached on the coverslip were washed with PBS and then
fixed with 2% Paraformaldehyde (PFA) (formaldehyde in
PBS, pH 7.4) for 20 min at room temperature. The PFA
was then removed and the coverslip was washed three times
with PBS over a 15-min period. Pre-chilled (−20◦C) 70%
ethanol was added and the coverslip was incubated for 20
min at room temperature. Ethanol was removed and the
coverslip was washed with PBS three times over a 15-min
period. Then the coverslip was incubated in blocking solu-
tion 5% BSA in PBS-TT (PBS containing 0.5% Tween 20,
0.1% Triton X-100) for 1 h at room temperature. Gamma-
H2AX primary antibody incubation was carried out in 1%
BSA in PBS-TT buffer (antibody dilution was 1:500). After
2–3 washes with PBS (5 min each), the coverslips were in-
cubated with Alexa Fluor 555 Goat anti-mouse antibody at
a dilution of 1:500 in 1% BSA in PBS-TT for 1 h at room
temperature. Then the cells were washed with PBS for 3–
5 times, each time for 5 min with slow shaking. Cells were
counterstained with DAPI mounting medium. Images were
captured using a DeltaVision microscopy imaging system
(40× objective) in the CRC, LRBGEFluorescence Imaging
Facility (NIH). Total intensity per nucleuswasmeasured us-
ing image J software (NIH).
Paclitaxel treatment
Our experiment protocol was described previously (36).
UWB1.289 cells carrying alphoidtetO-HAC/BRCA1 and
isogenic cells that have lost the HAC were treated with vari-
ous doses of the drug (0–1 nM) for 24 h.At the end of the ex-
periment,MTS tetrazolium cell viability assay was done ac-
cording to themanufacturer’s instructions (TheCellTiter 96
AQueous One Solution Cell Proliferation Assay, Promega).
Experiments were carried out in triplicate.
Transcription timing analysis
UWB1.289 cells containing alphoidtetO-HAC/BRCA1 and
the same cells after HAC loss were incubated with 20 M
EdU for 3.5 h. Then cells were fixed, permeabilized and click
labeled with modified Alexa Fluor647 azide using Click-iT
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Plus EdU Flow Cytometry Assay Kits (Molecular Probes,
# C10632) according to the manufacturing protocol with
minor modifications. These modification include five times
dilution of Click-iT fixative (Component D) by PBS. Then,
500 l of 1× Click-iT saponin-based permeabilization and
wash reagent were added to the stained cells and proceed
to the next step for staining the cells for DNA content by
FxCycle Violet stain (Molecular Probes, # F10347). The
staining procedure was performed according to the manu-
facturing protocol. After staining UWB1.289 cells contain-
ing alphoidtetO-HAC/BRCA1 and after HAC loss the cells
were sorted on a flow cytometer to separate the cells for G1
and S phases of the cell cycle. The sorting parameters were
as follows: 635 nm excitation and a 660/20 nm bandpass
emission filter for detection of the EdU Alexa Fluor647 pi-
colyl azide and 405 nm excitation and a 450/40 bandpass
emission filter for detection of the FxCycle Violet fluores-
cence. The sorted cells were used for total RNA purifica-
tion, cDNA synthesis and analysis of the transcription of
centromere regions by qPCR using specific primes (Supple-
mentary Table S1).
Statistical analysis
Statistical analysis was made using Prism (GraphPad Soft-
ware Inc., La Jolla, CA, USA). An unpaired Student t-test
and, Chi square test and two way ANOVA were used. P <
0.05 was considered significant.
RESULTS
Construction of the HAC module carrying the full-length
BRCA1 gene
A total of 90 kb of genomic DNA including the BRCA1
gene was previously isolated as a circular YAC by a TAR
cloning technique (23) (Figure 1a, Step 1 and Supplemen-
tary Figure S1). To prepare this YAC BRCA1-containing
molecule for insertion into the alphoidtetO-HAC, the YAC
clone was converted into YAC/BAC using a yeast-bacteria-
mammalian cell retrofitting vector pJBRV1 (22) (Figure 1a,
Step 2). The pJBRV1 vector contains a 3′ HPRT-loxP cas-
sette. This allows gene loading into the unique loxP site of
the alphoidtetO-HAC in hamster CHO cells by Cre-loxPme-
diated recombination. The retrofitting protocol is shown in
Supplementary Figure S2.
To insert the 90 kb genomic copy of the BRCA1 gene
into the HAC, the appropriate YAC/BAC construct and
a Cre-recombinase expression vector were co-transfected
intoHPRT-minus CHO cells carrying the alphoidtetO-HAC
(Figure 1a, Step 3). A control for quality of BAC DNA
is important to efficient gene loading into the HAC. Most
of the molecules should be in a covalently closed form
(see Supplementary Figure S3). Insertion of the gene into
the HAC reconstitutes a functional HPRT gene (Supple-
mentary Figure S4), so HPRT-plus colonies were selected
on HAT medium. HPRT reconstitution was confirmed by
PCR using a set of specific primers (Supplementary Table
S1). Integrity of the BRCA1 gene after insertion into the
HAC was confirmed by PCR-amplification of all exon se-
quences (Figure 1b) using a set of BRCA1-specific primers
(Supplementary Table S1). Notably, that only 4 among 30
HPRT-plus colonies selected on HAT medium contained
all BRCA1 exons. Such a high rate of deletion of BRCA1
sequences during gene loading into the HAC is presum-
ably due to an abnormal density of Alu repeats represent-
ing more than 70% of the BRCA1 gene sequence (37) that
can recombine leading to deletions. Note that no dele-
tions were observed after loading of other genes into the
HAC (22). Examples of the observed deletions are shown
in Supplementary Figure S5. We term the resulting HAC
clones containing allBRCA1 exon sequences as alphoidtetO-
HAC/BRCA1.
A representative FISH image of one alphoidtetO-
HAC/BRCA1 clone in CHO cells is shown in Figure 1c.
As seen, the HAC is maintained autonomously and the
HAC signal co-localizes with the BRCA1 gene signal
on metaphase chromosome spreads. Because antibodies
against human BRCA1 recognize a band with mobility
of hBRCA1 on western blots with the CHO cell lysate,
we used RT-PCR analysis to confirm expression of the
human BRCA1 gene. RT-PCR products of the predicted
size were obtained for four clones containing all exons
(Figure 1d), and their identity was confirmed by sequencing
(Supplementary Figure S6).
Physiological tests proving functionality of BRCA1 encoded
on the HAC
For genetic complementation assays, the BRCA1-
containing HAC was transferred from CHO cells to
UWB1.289 BRCA1-deficient human cells via MMCT (Fig-
ure 1a, Step 4). FISH analysis of five randomly chosen BSR
clones showed that alphoidtetO-HAC/BRCA1 propagates
autonomously in these cells without detectable integration
into chromosomes. A FISH image showing detection of
alphoidtetO-HAC/BRCA1 in one representative clone is
shown in Figure 1e. Western blot analysis of five HAC
positive UWB1.289 clones revealed that they all express
BRCA1 (Figure 1f). To confirm that BRCA1 is expressed
from the HAC, we targeted the tTS repressor fusion
protein to the centromere of the alphoidtetO-HAC/BRCA1
as described previously (19,20,22). The targeting resulted
in a high frequency of HAC loss (Figure 1a, Step 5).
Based on FISH and western blot analysis, cells that lost
the HAC no longer expressed BRCA1 (Supplementary
Figure S7). We used five independent tests outlined below
to demonstrate the functionality of BRCA1 expressed from
the alphoidtetO-HAC/BRCA1 vector.
First test: It is well known that BRCA1 plays a critical
role in damage responses to DNA double-strand breaks
(DSBs) (4) and within seconds of the generation of DSBs
histone H2AX molecules accumulate in foci at sites of
DNA damage. These foci then rapidly disappear as the
damage is repaired, a process that requires BRCA1 func-
tion. To follow the processing of DSBs after irradiation (2
Gy), the total intensity of gamma-H2AX foci was mea-
sured at 15 h post-irradiation in UWB1.289 cells carrying
alphoidtetO-HAC/BRCA1 and in isogenic cells that been in-
duced to lose the HAC. Figure 2a depicts selected fluores-
cence microscopy images of non-irradiated (NR) and irra-
diated cells. When we scored the persistence of the DNA
damage foci as defined by gamma-H2AX staining, a sta-
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Figure 1. Scheme of consecutive experimental steps from selective BRCA1 gene isolation in yeast S. cerevisiae to its expression in the UWB1.289 BRCA1-
deficient human cells. (a) Step 1: A direct TAR isolation of the BRCA1 gene from human genomic DNA. TAR vector contains two gene targeting hooks
(green and blue boxes), a yeast centromeric locus (CEN) and a yeast selectable marker HIS3. Recombination between targeting sequences in the TAR
vector and the targeted sequences of the genomic DNA fragment leads to the rescue of the BRCA1-containing loci as a circular TAR/YACmolecule. Step
2: Retrofitting of the circular TAR/YAC isolate containing the full-length BRCA1 gene by pJBRV1 vector containing a 3′ HPRT-loxP-eGFP cassette.
Recombination of the BamHI-linearized pJBRV1 vector with a TAR/YAC in yeast leads to replacement of the ColE1 origin of replication by the F’′ factor
origin of replication that allows enable subsequent propagation in a BAC form. Step 3:BRCA1 gene loading into a unique loxP site of the alphoidtetO-HAC
(tetO-HAC) by Cre-loxP recombination system in hamster CHO cells. Step 4: MMCT of alphoidtetO-HAC/BRCA1 from CHO into the human BRCA1-
deficient UWB1.289 cells for complementation analyses. Step 5: Elimination of the alphoidtetO-HAC/BRCA1 from UWB1.289 cells by expression of the
tTS fusion construct. (b) PCR analysis of the TAR clones containing the full-length BRCA1 gene for the presence of exons before and after retrofitting
in yeast and after BRCA1 insertion into a loxP site of the alphoidtetO-HAC in CHO cells. The numbers above correspond to the exon number (from 1 to
24). M, ladder. (c) FISH analysis of the alphoidtetO-HAC/BRCA1 in CHO cells using specific probes for HAC vector (in red) and for cDNA BRCA1 gene
sequences (in green). (d) Transcriptional analysis of the human BRCA1 gene in CHO cells. Lane 1 corresponds to a positive control: RT-PCR of RNA
purified from human MCF7 cells. Lane 2 corresponds to a negative control: RT-PCR of RNA purified from CHO cells. Lanes from 3 to 6 correspond to
RNA purified from five independently obtained alphoidtetO-HAC/BRCA1-containing CHO clones. Lane 7 corresponds to the RT-PCR product of the
controlERCCA2 gene. Clones 3, 4, 5 and 6 are BRCA1-positive. All primers designed are presented in Supplementary Table S1. The bands have a predicted
size of RT-PCR products. All amplified fragments were gel-purified and sequenced and proved the identity of products to the human BRCA1 transcripts.
M, ladder. (e) FISH analysis of the alphoidtetO-HAC/BRCA1 in UWB1.289 cells using specific probes for HAC vector (in red). (f) Western blot analysis
of BRCA1-deficient UWB1.289 cells, alphoidtetO-HAC/BRCA1-containing UWB1.289 cells (five independently obtained clones after MMCT transfer
from the clone #4 of CHO cells) using human-specific Abs against BRCA1. BRCA1 inserted into the alphoidtetO-HAC produces a protein of the predicted
size. The human breast adenocarcinoma MCF7 cell line (hemizygous for the BRCA1 wild type with a reduced BRCA1 expression) was used as a positive
control for expression of BRCA1.
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Figure 2. Complementation tests for functionality of BRCA1 in UWB1.289 cells. (a) Accumulation of  -H2AX in BRCA1-deficient cells (UWB1.289)
carrying alphoidtetO-HAC/BRCA1 and in the cells that have lost the HAC after exposure to 2 Gy of  -rays. Cells were stained 15 h after irradiation
with anti- -H2AX antibodies (red) and with DAPI (blue). Representative microscopic fluorescence images of  -H2AX foci accumulation are shown. (b)
Quantitative data for  -H2AX foci processing. Cells were collected after 15 h and the average number of  -H2AX foci was quantified in BRCA1-positive
and BRCA1-negative cells. NR cells have been included as a control. (c) Radiation sensitivity clonogenic survival assay. BRCA1-deficient UWB1.289 cells
are radiation sensitive. Cells carrying alphoidtetO-HAC/BRCA1 and after HAC loss were plated in triplicate and irradiated with the indicated doses (from
0 to 8 Gy). Cells were stained with crystal violet and counted visually. Clonogenic survival was calculated as a number of colonies present in each plate
normalized to the number of colonies in the NR control plates. Cells carrying alphoidtetO-HAC/BRCA1 (red) are less sensitive than the cells that lost the
HAC (blue). Bars, mean of triplicate samples. (d) Co-immunoprecipitation analysis of BRCA1 and pol  proteins interaction. Cell extracts from the cells
carrying alphoidtetO-HAC/BRCA1 and from the cells that have lost the HAC were immunoprecipitated with anti-pol  antibody or non-immune IgG.
Immunoprecipitated proteins were detected by SDS-polyacrylamide gel electrophoresis and immunoblotting. (e) Viability of UWB1.289 cells carrying
alphoidtetO-HAC/BRCA1 (red) and after HAC loss (blue) after treatment with paclitaxel. At 24 h after treatment the cell viability was measured. All
experiments were repeated three times with each sample prepared in triplicate.
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tistically significant difference was observed between the
two isogenic cell lines (P < 0.05). The number of foci and
consequently the total intensity of the gamma-H2AX flu-
orescence was significantly increased in the cells that have
lost the alphoidtetO-HAC/BRCA1 (Figure 2b). This indi-
cates that after 15 h post-irradiation many DSBs are still
unrepaired. A similar observation that radiation-induced
gamma-H2AX foci are higher in BRCA1-deficient cells
compared to isogenic cells expressing BRCA1 has been pre-
viously reported (4).
Second test: Prior studies have shown that UWB1.289
cells are radiation sensitive in clonogenic survival assays and
that BRCA1 expression partially corrects this sensitivity
(27). Therefore, we compared the colony formation capac-
ity of UWB1.289 cells carrying alphoidtetO-HAC/BRCA1
with that of isogenic cells that had lost the HAC in response
to increasing doses of irradiation up to 6 Gy. As expected,
UWB1.289 cells carrying alphoidtetO-HAC/BRCA1 cells
exhibited greater resistance to irradiation than isogenic cells
following induction of HAC loss (Figure 2c) [ANOVA F (1,
4) = 37.27, P = 0.0036].
Third test: Recent studies have demonstrated a part-
nership between BRCA1 and DNA polymerase  in
the base excision repair pathway (33). Therefore, we
looked for interactions between the two proteins using
co-immunoprecipitation analysis. For this purpose, ex-
tracts from UWB1.289 cells expressing BRCA1 (carry-
ing alphoidtetO-HAC/BRCA1) and from isogenic cells that
had lost the HAC were prepared and subjected to im-
munoprecipitation using anti-pol  or anti-BRCA1 anti-
bodies. As expected, BRCA1 co-immunoprecipitated with
pol  antibody (IP with anti-pol ) from extracts of
cells carrying alphoidtetO-HAC/BRCA1 (e.g. expressing
BRCA1), whereas no immunoprecipitation was observed
using extracts from cells that have lost the alphoidtetO-
HAC/BRCA1 (Figure 2d). As an additional negative con-
trol, immunoprecipitation experiments were performed us-
ing non-immune IgG. These results confirm that human
BRCA1 expressed from alphoidtetO-HAC physically inter-
acts with pol  (33).
Fourth test: Zhou et al. (38) showed that BRCA1 helps
to mediate resistance to paclitaxel, the most commonly
used chemotherapy drug for patients with ovarian can-
cer. We therefore measured the viability of UWB1.289 cells
(which come from an ovarian carcinoma) either carrying
alphoidtetO-HAC/BRCA1 and after loss of the HAC in re-
sponse to a range of paclitaxel concentrations (0–1 nM) for
24 h. The percentage of viable UWB1.289 cells expressing
BRCA1 after exposure to the drug was higher than the per-
centage of cells that had lost the HAC (Figure 2e) [ANOVA
F (1, 4) = 13.43, P= 0.0215]. Thus, the loss of BRCA1 sen-
sitizes UWB1.289 cells to paclitaxel.
Fifth test: To investigate whether the presence of the func-
tional BRCA1 gene is required for accurate chromosome
segregation, we performed a micronucleus formation assay
(MNi) in UWB1.289 cells either expressing BRCA1 from
the HAC or after HAC loss. This assay revealed a signifi-
cant difference in MNi formation between cells expressing
BRCA1 (24%) and BRCA1-deficient cells (38%) (Table 1).
Our results therefore support previous reports that BRCA1
is required for accurate chromosome segregation (4,39,40).
To summarize, our five test experiments demonstrated
that the alphoidtetO-HAC/BRCA1 vector expresses a func-
tional BRCA1 protein.
BRCA1 functions to promote maintenance of heterochro-
matin domains within a functional human kinetochore
Recently Zhu et al. (9) reported that BRCA1 deficiency re-
sults in transcriptional de-repression of tandemly repeated
satellite DNA in mouse and human, including those spe-
cific for centromeric loci. In mouse cells, their results clearly
showed that both centromeric and pericentromeric regions
are affected by BRCA1 deficiency. Such analysis was pos-
sible because these two regions are formed on different
types of repeated sequences, i.e. minor and major satellites.
In human centromeric regions, most alpha-satellite DNA
repeats (∼90%) are organized into chromosome-specific
HORs (26) that directly involved in kinetochore assembly.
Therefore, two main domains of the human kinetochore,
centrochomatin and heterochromatin, are assembled on the
same DNA sequences. Such organization complicates the
analysis of human centromeric repeats within a functional
kinetochore in the human BRCA1-deficient cells. In their
work, Zhu et al. used the primers that were not specific
to HORs of any individual chromosome (9). Thus, their
primers recognized only aminor fraction of diverged alpha-
satellite DNA monomers localized outside of the major
block of alpha-satellite DNA.
Taking an advantage that a complete sequence represen-
tation of alpha-satellite monomers across centromeric re-
gions of the most human chromosomes became available
(26) in our study, we focused on well-characterized HORs
of several human chromosomes. Initially, we chose single
predominant HOR blocks on chromosome 21 (30) and on
chromosome X (41), that are required for kinetochore func-
tion, for qRT-PCR analysis. Transcription of satellite DNA
in these regions was found to be 20- to 30-fold de-repressed
in cells that had been ‘cured’ of alphoidtetO-HAC/BRCA1,
i.e. in the cells that became BRCA1-deficient relative to
the isogenic cells expressing functional BRCA1 (Figure 3a)
[chr21a t(4) = 5.7845, P= 0.0044; chr21b t(4) = 21.3600, P
< 0.0001; chrX t(4) = 5.2025, P = 0.0065]. Next, we de-
termined the timing of transcription of these regions in-
duced by BRCA1 deficiency. For this purpose, an asyn-
chronous population of human cells was pulse-labeled with
EdU. EdU-treated cells were sorted by FACS to two frac-
tions: G1 and S. In each fraction replicating sequences were
quantified by qPCR using specific primers (Supplementary
Table S1). As seen from Figure 3b, transcription occurs
within G1-S phases when the majority of human genes
are expressed. We also investigated the effects of BRCA1
loss on transcription of pericentromeric satellite 2 (Sat2),
a heterochromatic locus mapped within 10q21, and also
observed de-repressed in cells that have lost alphoidtetO-
HAC/BRCA1 [SAT2 t(4) = 11.3205, P = 0.0003] (Fig-
ure 3c). In separate experiments, we checked the chromatin
status of the analyzed regions after loss of BRCA1. Specif-
ically, enrichment in H3K4me3 (a marker for active tran-
scription) and H3K9me3 (a marker for heterochromatin)
were evaluated by ChIP analysis. As seen from Supplemen-
tary Figure S8, loss of BRCA1 was accompanied by a de-
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Figure 3. De-repression of alpha-satellite DNA transcription in BRCA1-deficient UWB1.289 cells. (a, c and d) Quantitative RT-PCR experiments showing
that the satelliteDNA transcripts ofHORs regions of the chromosome 21 (chr21a and chr21b), chromosomeX (chrX) (a), chromosome 5 (D5Z1 andD5Z2)
(d) and DNA transcripts of pericentromeric Sat2 repeats located at 10q21 (c) are significantly repressed in the cells carrying alphoidtetO-HAC/BRCA1
compared to that of the cells that have lost the HAC. Ct values were normalized relative to each other. Error bars indicate SD. (b) Timing of transcription
of HORs regions of chromosome X and chromosome 21. (e) ChIP analysis of different centromeric regions using antibodies against CENP-B (centromeric
protein B) in BRCA1-deficient UWB1.289 cells containing alphoidtetO -HAC /BRCA1 and in the same cells that have lost the HAC. (f) Quantitative RT-
PCR experiments showing the transcripts of the double homeobox 4 (DUX4) gene located in the heterochromatic subtelomeric 4q35 region, the cancer-testis
SPANX-B gene located at the Xq27 region and, as a control, a housekeeping gene PPIH, peptidyprolyl isomerase H (cyclophilin H) was used. Asterisk
denotes significant difference.
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Table 1. Micronuclei (MNi) formation in the HAC/BRCA1-containing UWB1.289 cells and in the same cells that have lost the HAC
Experiment No Mni Mni Total %Mni Mean ± SD (%)**
BRCA1 positive (A)* 155 53 208 25.5 24.7±1.1
BRCA1 positive (B) 156 49 205 23.9
BRCA1 negative (A) 129 81 210 38.6 38.5±0.1
BRCA1 negative (B) 125 78 203 38.4
A, the first experiment; B, the second experiment.
**Number of MN is given as means ± SD in two independent experiments. There is a significant difference between BRCA1 positive and BRCA1 negative
cells [χ2 (1) = 18.20, P < 0.0001].
tectable decrease in levels of the heterochromatin marker at
centromere 21 [chr21 t(4) = 9.7901, P = 0.0006]. No signif-
icant changes were seen in H3K4me3, but as this mark is
typically found proximal to promoters, small local changes
may not have been detectible in our analysis (Supplemen-
tary Figure S8).
Alpha-satellite or alphoid DNA sequences in HORs are
organized into two types of chromatin, heterochromatin
(surrounding the kinetochore) and centrochromatin (within
the kinetochore domain) corresponding to transcription-
ally competent chromatin (41–43). To clarify which com-
partment of alphoid DNA repeats is predominantly tran-
scribed in BRCA1-deficient cells, we took an advantage of
human chromosomes 5 where heterochromatin and cen-
trochromatin are formed on two differentHORs:D5Z1 and
D5Z2.These arrays can be distinguished by PCR (32,44,45).
Earlier ChIP and PCR analyses revealed that the kineto-
chore forming CENP-A domain is predominantly local-
ized to D5Z2 while being largely excluded from the peri-
centromeric D5Z1 domain in a range of human cell lines
(32). It is also known that D5Z2 possesses intact CENP-B
box sequences (46), a 17 bp motif necessary for binding of
the CENP-B protein.
We first checked the CENP-A status on these HORs in
BRCA1-deficient UWB1.289 cells as well as in the same
cells carrying alphoidtetO-HAC/BRCA1 (Supplementary
Figure S9) and confirmed that CENP-A is significantly en-
riched on D5Z2 compared to D5Z1 [BRCA1 positive cells
[t(4) = 4.6093, P = 0.0100; BRCA1 negative cells t(4) =
28.1423, P < 0.0001]. Further, RT-RCR analysis of these
regions revealed that transcription is specifically activated
within alphoid DNA repeats that are organized into peri-
centromeric heterochromatin domains, i.e. D5Z1 following
the loss of the HAC (Figure 3d) [D5Z1 t(4) = 14.8956,
P = 0.0001]. Next, we investigated the CENP-B status on
chromosome 5 as well as on chromosome 21 in BRCA1-
deficient UWB1.289 cells as well as in the same cells car-
rying alphoidtetO-HAC/BRCA1. As seen, the level of the
CENP-B protein was not significantly affected by the lack
of BRCA1 (Figure 3e).
To ask whether the de-repression upon loss of func-
tional BRCA1 described above for certain alpha-satellite
loci is indicative of a loss of silencing genome-wide, the
transcriptional status of two known human silenced genes,
SPANX-B and DUX4 was examined. SPANX-B belongs to
the SPANX (sperm protein associated with the nucleus on
the X chromosome) gene family of cancer-/testis-specific
antigens whose expression is restricted to the normal testis
and certain tumors (47–49). These genes are located in
segmental duplications at Xq27. The double homeobox 4
(DUX4) gene is located within a 3.3 kb dispersed repeat
family that is represented by 10–100 tandem copies on the
D4Z4 repeat array in the heterochromatic subtelomeric re-
gion 4q35 (50,51). No significant de-repression of transcrip-
tion of SPANX-B genes was observed in BRCA1-deficient
cells (Figure 3e). However, we observe transcriptional de-
repression forDUX4 [t(4)= 4.8639,P= 0.0083] in BRCA1-
deficient cells in comparison with UWB1.289 cells express-
ing BRCA1 (Figure 3f).
Thus, our data obtained by a different approach and
focused on other chromosome loci are in agreement with
those obtained by Zhu et al. (9) and indicate that BRCA1
functions to promote heterochromatin silencing in a ge-
nomic locus-specific manner. In addition, we analyzed
chromosome-specific HORs. This analysis revealed that
BRCA1 deficiency activates transcription of alpha-satellite
HORs assembled in heterochromatin domains essential for
the kinetochore function. Such activationmay explain chro-
mosome instability observed in cells lacking a functional
BRCA1.
Expression of the human BRCA1 gene from the HAC-
BRCA1 module in porcine cells
The portable HAC module could be potentially used for
development of a pig model for breast cancer (52), which
offers an alternative to mouse models that do not faith-
fully mimic the relevant human disease. As the first step
toward such a model, we have transferred the BRCA1-
containing HAC from CHO cells to the pig’s testis fi-
broblast ST cells using MMCT technique (Figure 4a).
FISH analysis of porcine cells containing the alphoidtetO-
HAC/BRCA1 in two clones, pl4 and pl5, confirmed an
autonomous form of the HAC in the cells without de-
tectable integration into chromosomes (Figure 4b). The
BRCA1-HAC module contains the eGFP transgene that
is also expressed. Fluorescence image of cells carrying
the alphoidtetO -HAC/BRCA1/eGFP is shown in Fig-
ure 4c. Expression of human BRCA1 in ST cells bearing
alphoidtetO-HAC/BRCA1was confirmed by RT-PCR (Fig-
ure 4e and Supplementary Figure S10) by using primers that
specifically amplify the human BRCA1 but not the porcine
BRCA1 gene (Supplementary Table S1).
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Figure 4. Expression of the human BRCA1 gene in porcine ST cells. (a) From hamster CHO cells exhibiting a high efficiency of microcell formation, the
alphoidtetO -HAC/BRCA1 was transferred into the pig’s testis fibroblast ST cells using MMCT technique. (b) FISH analysis of porcine cells containing
the alphoidtetO-HAC/BRCA1. Chromosomal DNA was counterstained with DAPI (blue). Arrow indicates to the HAC. (c) Fluorescence image of cells
carrying the alphoidtetO -HAC/BRCA1 containing the expressed eGFP transgene. (d) Expression of the human BRCA1 gene in porcine cells. RT-PCR
analysis of genomic DNA isolated from the original ST cells (lane 4), from two porcine clones (pl4 and pl5) containing the alphoidtetO -HAC/BRCA1
(lanes 2 and 3) and from the human HeLa cells as a positive control (lane 1) using the human BRCA1-specific primers (Supplementary Table S1). The size
of the predicted product is 839 bp. M-ladder containing alphoidtetO -HAC/BRCA1
DISCUSSION
In our previous work, we converted the alphoidtetO-HAC, a
synthetic artificial human chromosome with a kinetochore
that can be inactivated by targeting of chromatin modifiers
(19), into a vector able to stably maintain cloned genomic
loci over multiple cell generations (20). This HAC contains
a unique loxP site that allows selection for gene loading.
We previously demonstrated that the alphoidtetO-HAC vec-
tor could deliver and stably maintain genomic copies of two
functional human genes,VHL andNBS1, and complement
the corresponding genetic deficiencies in patient-derived cell
lines (22).
In the present study, the alphoidtetO-HAC was used for
delivery and expression of a 90-kb genomic region encod-
ing the functional BRCA1 gene. We demonstrated that the
BRCA1 gene isolated by TAR cloning (24,25) can be in-
troduced into the alphoidtetO-HAC, resulting in indefinite
propagation of the artificial chromosome in hamster CHO
cells. Because CHO cells exhibit a high efficiency of micro-
cell formation, this enables transfer of theHAC to other cell
types via MMCT (28,29). The alphoidtetO-HAC/BRCA1
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was accordingly transferred into the ovarian carcinoma cell
line UWB1.289, derived from a patient with a BRCA1 de-
ficiency. Functional expression of BRCA1 in recipient cells
was proven by a set of five independent tests, based on the
known functions of the protein. Importantly, this system
allows corresponding controls to be conducted in isogenic
cells, following elimination of the HAC from the cells after
targeted inactivation of its kinetochore.
An important property of the alphoidtetO-HAC is its abil-
ity to support long-term expression of cloned genes without
transgene-induced silencing. Thus, no significant changes
in the level of BRCA1 expression were detected after more
than 6 months of propagation of alphoidtetO-HAC/BRCA1
in the patient-derived cell line that is in agreement with our
results obtained with other genes loaded in the HAC (22).
In this work, we examined the recently proposed role of
BRCA1 inmaintenance of heterochromatin integrity within
pericentromeric and centromeric satellite repeats. A link be-
tween BRCA1 foci and pericentromeric chromatin was ob-
served several years ago (1). More recently, Zhu et al. (9)
identified histone H2A as a specific substrate of BRCA1
within pericentromeric satellite DNA in both mouse and
human. Their study reported that depletion of BRCA1 re-
sults in de-repression of satellite DNA transcription and
abnormal heterochromatin structure. Although the mech-
anism is not known, it is likely to involve decreased levels of
the monoubiquitylated histone H2A (UbH2A).
For human cells, three types of human satellite repeats,
satellite III (localized on the short arms of acrocentric chro-
mosomes and in the heterochromatin of the long arms of
chromosome 1, 9 and Y), gamma-satellite (localized on the
chromosome X) (53) and alphoid DNA were analyzed by
RT-PCR in the original study (9). However, the alphoid
DNA families amplified by chosen primers were not distin-
guished in the prior study and the genomic positions of the
transcribed sequences of these repeats cannot be mapped
unambiguously. Also, it is difficult to conclude what frac-
tion of the repeats is transcribed.
In our work, using the alphoidtetO-HAC carrying the
full-length BRCA1 gene we carried out a more detailed
analysis of chromatin status of chromosome-specific alpha-
satellite repeats after loss of BRCA1. For this purpose,
we chose well-characterized alpha-satellite regions corre-
sponding to megabase-size HORs of human chromosomes
21 and X. For each HOR, specific diagnostic primers were
used, allowing us to cover∼90% of the alpha-satellite DNA
monomers in these chromosomal alphoid arrays (26). This
analysis revealed that a loss of theBRCA1 gene is accompa-
nied by 20- to 30-fold increase of alphoid DNA transcripts
within HORs of these two chromosomes. Transcription was
also activated within pericentromeric satellite 2 repeats lo-
cated at 10q21, a region that is commonly used as a con-
trol to define pericentromeric heterochromatin (19,30). In
the same experiments, a detectable increase in the level of
transcription was observed at one region enriched in hete-
rochromatin, i.e. for the peritelomeric region 4q35 (51), and
no increase for a genomic region carrying cancer-testis spe-
cific genes at Xq27 (47). Thus, these data agree with those
obtained by Zhu et al. (9) and indicate that BRCA1 func-
tions to promote transcriptional silencing of heterochro-
matin in a genomic locus-specific manner.
To clarify which fraction of alphoid DNA repeats, orga-
nized into heterochromatin or centrochromatin, is predom-
inantly transcribed in BRCA1-deficient cells, we analyzed
HOR arrays of the human chromosome 5, which consists of
two different blocks of alphoid DNA repeats. This analysis
clearly demonstrated that transcription is specifically acti-
vated within alphoid DNA repeats that are organized into
heterochromatin domains that are distal to the kinetochore
forming alpha-satellite arrays.
It is well documented that loss of BRCA1 is accompa-
nied by chromosome instability (4,39,40). One accepted ex-
planation for defects in chromosome transmission is due to
misregulation of centrosome copy number (54). However,
elevated transcription of centromeric repeats can also lead
to kinetochore disassembly (42). Based on this observation
and our data on analysis of HORs transcription, we pro-
pose that impairment of kinetochore function due to ele-
vated transcription may also contribute chromosome insta-
bility in BRCA1-deficient cells and may contribute to cellu-
lar transformation.
Large heterochromatic blocks of satellite DNA are typ-
ically clustered in the nucleus and could provide anchor
points for genomic organization. De-regulated transcrip-
tion in these regions in BRCA1-deficient cells would be ex-
pected to lead to epigenetic alterations that could impact on
regulation of nearby gene(s) and nuclear structural interac-
tions (55). It is worth noting that there are multiple lines of
evidence to support the idea that overexpression of satellite
DNA and other repetitive elements may be widely prevalent
in many types of cancer (56,57).
An increasing set of evidence strongly indicates that a
principal tumor suppressor activity of BRCA1 is a repair
of DNA damages (58,59). Clarification of a role of chro-
mosome instability in cell transformation will require ad-
ditional experiments of which functional complementation
like that reported here may contribute important informa-
tion. The portable HAC module carrying the full-length
BRCA1 gene should be useful for analysis of the tumor
suppressor function of BRCA1. As mentioned above, the
HAC/BRCA1module assembled in hamster CHO cells can
be transferred into any recipient cells, including transgenic
animals. For example, the module could potentially be used
for development of a pigmodel for breast cancer (52), which
offers an alternative to mouse models that do not faith-
fully mimic the relevant human disease. As the first step to-
ward such a model, we have demonstrated the stable prop-
agation of the alphoidtetO-HAC/BRCA1 and expression of
hBRCA1 in porcine cells.
To summarize, we have here constructed a portable
BRCA1-HAC module and demonstrated its utility for de-
livery of the full-length BRCA1 gene and correction of ge-
netic deficiencies in human and porcine cells. Using this
module, in which the full-length transcript, including any
splice variants and intronic signals, can be expressed in cell
lines or removed from them without altering the genomic
DNA complement, we have extended an earlier study (9)
suggesting that BRCA1 is required for the normal silenc-
ing of certain DNA repeats. More importantly, we demon-
strated a clear link between specific disruption of cen-
tromeric heterochromatin essential for kinetochore and loss
of BRCA1 function. A BRCA1-HAC module is available
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